Advances in Monitoring and Reversal Strategies for the Novel Anticoagulants Factor Ⅺ Inhibitors

Factor Ⅺ (FⅪ) plays a major role in thrombus amplification and an ancillary role in hemostasis. This differential contribution is expected to provide new ideas for the prevention and treatment of thrombotic diseases by targeting FⅪ as a potentially safer anticoagulation strategy. Currently, an increasing number of FⅪ inhibitors are entering phaseⅢ clinical trials, and although these inhibitors showed promising clinical potential, the strategies for monitoring and reversing the effects of these inhibitors remain unclear, which poses new challenges for laboratory monitoring and clinical practice. This review, based on the physiological function of FⅪ and FⅪ inhibitors under study, systematically explored the laboratory evidence of coagulation activity linked to these inhibitors, summarized potential methods of reversal in combination with the treatment protocols of inherited FⅪ deficiency, which provided certain references for the development of clinical treatment protocols and reversal strategies.